Skip to main content
. Author manuscript; available in PMC: 2021 Oct 15.
Published in final edited form as: Cancer Res. 2021 Feb 16;81(8):2086–2100. doi: 10.1158/0008-5472.CAN-20-2218

Figure 4. Ritanserin treatment rewires purine metabolism in Tsc2-deficient cells.

Figure 4.

(A) Hierarchical clustering and heat map showing the top 50 differential metabolites in ritanserin treated Tsc2−/− MEFs. (B) Metabolite Set Enrichment Analysis (MSEA) identified differentially regulated metabolic pathways with FDR q<0.05. (C-G) LC/MS reveals that pentose phosphate pathway intermediate metabolites are decreased upon ritanserin treatment (10uM; 16 hours). (H-I) Purines adenosine and guanine are decreased following ritanserin treatment. Data presented as mean ± SD of four biological replicates. Statistical significance was assessed using t-test with FDR correction (q<0.05) and *p<0.05, **p<0.01, ***p<0.001, ****p <0.0001.